TG Therapeutics Inc
TGTX
Company Profile
Business description
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
Contact
3020 Carrington Mill boulevard
Suite 475
MorrisvilleNC27560
USAT: +1 212 554-4484
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
264
Stocks News & Analysis
stocks
Tesla: Trump election may solidify near-term Tesla US EV leadership
Do possible benefits from the election make shares attractive?
stocks
ASX players that might thrive under a Trump administration
Recent election results have sent US markets into a record-high rally however implications remain mixed for the Australian share market. See our top ASX picks that could do better under a second Trump administration.
stocks
3 "buy the dip" candidates with wide moats
Share price pullbacks can present an opportunity to buy high quality companies at attractive prices.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,484.10 | 33.20 | 0.39% |
| CAC 40 | 7,216.83 | 10.15 | -0.14% |
| DAX 40 | 19,003.11 | 30.53 | -0.16% |
| Dow JONES (US) | 43,958.19 | 47.21 | 0.11% |
| FTSE 100 | 8,030.33 | 4.56 | 0.06% |
| HKSE | 19,823.45 | 23.43 | -0.12% |
| NASDAQ | 19,230.72 | 50.68 | -0.26% |
| Nikkei 225 | 38,883.71 | 162.05 | 0.42% |
| NZX 50 Index | 12,651.87 | 22.62 | -0.18% |
| S&P 500 | 5,985.38 | 1.39 | 0.02% |
| S&P/ASX 200 | 8,230.80 | 37.40 | 0.46% |
| SSE Composite Index | 3,439.28 | 17.31 | 0.51% |